







As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

S. Arjune reports the following:

Employer: University Hospital Cologne

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Sita Arjune

Manuscript ID: K360-2024-000244R1

Manuscript Title: Inflammatory cytokine levels in patients with autosomal dominant polycystic kidney disease

(ADPKD)

Date of Completion: June 26, 2024 Disclosure Updated Date: June 26, 2024









As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

F. Grundmann reports the following:

Employer: University of Cologne; Consultancy: partner: Alnylam, Vifor, GSK, AICURIS, Vertex;; Ownership Interest: partner: Bayer; Santa Barbara Nutrients;; Honoraria: see consultancy; Patents or Royalties: partner: : Detechgene;; and Advisory or Leadership Role: partner: : Scientific Advisory Board Santa Barbara Nutrients.;.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Franziska Grundmann

Manuscript ID: K360-2024-000244R1

Manuscript Title: Inflammatory cytokine levels in patients with autosomal dominant polycystic kidney disease

(ADPKD)

Date of Completion: July 18, 2024 Disclosure Updated Date: July 18, 2024









As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

K. Lettenmeier reports the following: Employer: University Clinic Cologne

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Katharina Leone Lettenmeier Manuscript ID: K360-2024-000244R1

Manuscript Title: Inflammatory cytokine levels in patients with autosomal dominant polycystic kidney disease

(ADPKD)

Date of Completion: June 24, 2024 Disclosure Updated Date: June 24, 2024









As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

E. Mahabir-Brenner has nothing to disclose.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Esther, Prof. Dr. Mahabir-Brenner Manuscript ID: K360-2024-000244R1

Manuscript Title: Inflammatory cytokine levels in patients with autosomal dominant polycystic kidney disease

(ADPKD)

Date of Completion: June 24, 2024 Disclosure Updated Date: June 24, 2024









As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

M. Majjouti reports the following:

Employer: Center for Molecular Medicine, University of Cologne (CMMC)

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Mohamed Majjouti

Manuscript ID: K360-2024-000244R1

Manuscript Title: Inflammatory cytokine levels in patients with autosomal dominant polycystic kidney disease

(ADPKD)

Date of Completion: July 2, 2024 Disclosure Updated Date: July 2, 2024









As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

R. Mueller reports the following:

Employer: Dept. II of Internal Medicine, University Hospital Cologne, University of Cologne; Consultancy: Alnylam, Vifor, GSK, AlCURIS, Vertex; Ownership Interest: Bayer; Santa Barbara Nutrients; Honoraria: see consultancy; Patents or Royalties: Detechgene; and Advisory or Leadership Role: Scientific Advisory Board Santa Barbara Nutrients.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Roman-Ulrich Mueller

Manuscript ID: K360-2024-000244R1

Manuscript Title: Inflammatory cytokine levels in patients with autosomal dominant polycystic kidney disease

(ADPKD)

Date of Completion: July 14, 2024 Disclosure Updated Date: July 14, 2024









As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

M. Späth reports the following:

Honoraria: BAYER AG; STADAPHARM GmbH

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Martin R. Späth

Manuscript ID: K360-2024-000244R1

Manuscript Title: Inflammatory cytokine levels in patients with autosomal dominant polycystic kidney disease

(ADPKD).

Date of Completion: June 25, 2024

Disclosure Updated Date: March 26, 2024









As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

P. Todorova reports the following: Employer: University Hospital Cologne

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Polina Todorova

Manuscript ID: K360-2024-000244R1

Manuscript Title: "Inflammatory cytokine levels in patients with autosomal dominant polycystic kidney disease

(ADPKD)"

Date of Completion: June 24, 2024 Disclosure Updated Date: June 24, 2024